Aytu BioPharma terminates AR101 asset purchase agreement; rights transferred to EnzCo

AYTU BIOPHARMA, INC

Company transferred all rights, title and interest in AR101 to EnzCo on August 5, 2025.
Termination extinguishes all obligations under the April 21, 2021 asset purchase agreement with Rumpus.
No penalties or remaining obligations for Aytu as a result of the termination.
Clinical development of AR101 had been previously suspended.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.